#BEGIN_DRUGCARD DB01586

# AHFS_Codes:
56:14.00

# ATC_Codes:
A05AA02

# Absorption:
Not Available

# Biotransformation:
Not Available

# Brand_Mixtures:
Not Available

# Brand_Names:
Actigall
Antigall
Arsacol
Cholit-ursan
Delursan
Destolit
Deursil
Dom-ursodiol c
Litursol
Lyeton
PHL-ursodiol c
PMS-ursodiol c
Peptarom
Solutrat
Ursacol
Urso
Urso 250
Urso DS
Urso forte
Ursobilin
Ursochol
Ursodamor
Ursofalk
Ursolvan

# CAS_Registry_Number:
128-13-2

# ChEBI_ID:
9907

# Chemical_Formula:
C24H40O4

# Chemical_IUPAC_Name:
(4R)-4-[(1S,2S,5R,7S,9S,10R,11S,14R,15R)-5,9-dihydroxy-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadecan-14-yl]pentanoic acid

# Chemical_Structure:
Not Available

# Creation_Date:
2007-08-29 08:57:33 -0600

# DPD_Drug_ID_Number:
2238984

# Description:
Ursodeoxycholic acid is an epimer of chenodeoxycholic acid (DB06777). It is a mammalian bile acid found first in the bear and is apparently either a precursor or a product of chenodeoxycholate. Its administration changes the composition of bile and may dissolve gallstones. It is used as a cholagogue and choleretic. [PubChem]

# Dosage_Forms:
Tablet	Oral

# Drug_Category:
Cholagogues and Choleretics

# Drug_Interactions:
Cholestyramine	The resin decreases the effect of ursodiol
Clofibrate	The fibric acid derivative decreases the effect of ursodiol
Clomifene	Estrogens decreases the effect of ursodiol
Colesevelam	Bile Acid Sequestrants may decrease the serum concentration of Ursodiol. Consider administration of ursodiol 5 hours or more after bile acid sequestrants to minimize ursodiol adsorption in the gastrointestinal tract. Monitor for decreased therapeutic effects of ursodiol in patients receiving bile acid sequestrants.
Colestipol	The resin decreases the effect of ursodiol
Conjugated Estrogens	Estrogens decreases the effect of ursodiol
Cyclosporine	Ursodiol increases the levels of cyclosporine
Diethylstilbestrol	Estrogens decreases the effect of ursodiol
Estradiol	Estrogens decreases the effect of ursodiol
Ethinyl Estradiol	Estrogens decreases the effect of ursodiol
Fenofibrate	The fibric acid derivative decreases the effect of ursodiol
Gemfibrozil	The fibric acid derivative decreases the effect of ursodiol

# Drug_Reference:
17019713	Akare S, Jean-Louis S, Chen W, Wood DJ, Powell AA, Martinez JD: Ursodeoxycholic acid modulates histone acetylation and induces differentiation and senescence. Int J Cancer. 2006 Dec 15;119(12):2958-69.
17335678	Smith T, Befeler AS: High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Curr Gastroenterol Rep. 2007 Mar;9(1):54-9.
17685473	Jackson H, Solaymani-Dodaran M, Card TR, Aithal GP, Logan R, West J: Influence of ursodeoxycholic acid on the mortality and malignancy associated with primary biliary cirrhosis: A population-based cohort study. Hepatology. 2007 Aug 8;46(4):1131-1137.

# Drug_Type:
Approved
Investigational
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
3.00

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
20 mg/L (at 20 °C)

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Ursodeoxycholic acid

# HET_ID:
IU5

# Half_Life:
Not Available

# InChI_Identifier:
InChI=1S/C24H40O4/c1-14(4-7-21(27)28)17-5-6-18-22-19(9-11-24(17,18)3)23(2)10-8-16(25)12-15(23)13-20(22)26/h14-20,22,25-26H,4-13H2,1-3H3,(H,27,28)/t14-,15+,16-,17-,18+,19+,20+,22+,23+,24-/m1/s1

# InChI_Key:
InChIKey=RUDATBOHQWOJDD-UZVSRGJWSA-N

# Indication:
The drug reduces cholesterol absorption and is used to dissolve (cholesterol) gallstones in patients who want an alternative to surgery.

# KEGG_Compound_ID:
C07880

# KEGG_Drug_ID:
D00734

# LIMS_Drug_ID:
1586

# Mechanism_Of_Action:
Ursodeoxycholic acid reduces elevated liver enzyme levels by facilitating bile flow through the liver and protecting liver cells.
The main mechanism if anticholelithic. Although the exact process of ursodiol's anticholelithic action is not completely understood, it is thought that the drug is concentrated in bile and decreases biliary cholesterol by suppressing hepatic synthesis and secretion of cholesterol and by inhibiting its intestinal absorption. The reduced cholesterol saturation permits the gradual solubilization of cholesterol from gallstones, resulting in their eventual dissolution.

# Melting_Point:
203 °C

# Molecular_Weight_Avg:
392.572

# Molecular_Weight_Mono:
392.292659768

# Organisms_Affected:
Humans and other mammals

# PDB_Experimental_ID:
1IHI

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
PA451837

# Pharmacology:
Ursodiol (also known as ursodeoxycholic acid) is one of the secondary bile acids, which are metabolic byproducts of intestinal bacteria. Primary bile acids are produced by the liver and stored in the gall bladder. When secreted into the colon, primary bile acids can be metabolized into secondary bile acids by intestinal bacteria. Primary and secondary bile acids help the body digest fats. Ursodeoxycholic acid helps regulate cholesterol by reducing the rate at which the intestine absorbs cholesterol molecules while breaking up micelles containing cholesterol. Because of this property, ursodeoxycholic acid is used to treat gall stones non-surgically.

# Predicted_LogP_Hydrophobicity:
3.01

# Predicted_LogS:
-4.3

# Predicted_Water_Solubility:
1.97e-02 g/l

# Primary_Accession_No:
DB01586

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
31401

# PubChem_Substance_ID:
46508795

# RxList_Link:
Not Available

# Salts:
Not Available

# Secondary_Accession_No:
Not Available

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
[H][C@@]1(CC[C@@]2([H])[C@]3([H])[C@@H](O)C[C@]4([H])C[C@H](O)CC[C@]4(C)[C@@]3([H])CC[C@]12C)[C@H](C)CCC(O)=O

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
(3alpha,5beta,7beta)-3,7-dihydroxycholan-24-oic acid
3,7-Dihydroxycholan-24-oic acid
3-alpha,7-beta-Dihydroxy-5-beta-cholanoic acid
3-alpha,7-beta-Dihydroxycholanic acid
3-alpha,7-beta-Dioxycholanic acid
3alpha,7beta-Dihydroxy-5beta-cholan-24-oic acid
5beta-Cholan-24-oic acid-3alpha,7beta-diol
7-beta-Hydroxylithocholic acid
7beta-Hydroxylithocholic acid
Acide ursodesoxycholique [inn-french]
Acido ursodeossicolico [italian]
Acido ursodeoxicolico [inn-spanish]
Acidum ursodeoxycholicum [inn-latin]
Chenodeoxycholic acid
Iso-ursodeoxycholic acid
UDCS
Ursodesoxycholic acid
Ursodiol

# Synthesis_Reference:
Not Available

# Toxicity:
Neither accidental nor intentional overdosing with ursodeoxycholic acid has been reported. Doses of ursodeoxycholic acid in the range of 16-20 mg/kg/day have been tolerated for 6-37 months without symptoms by 7 patients. The LD50 for ursodeoxycholic acid in rats is over 5000 mg/kg given over 7-10 days and over 7500 mg/kg for mice. The most likely manifestation of severe overdose with ursodeoxycholic acid would probably be diarrhea, which should be treated symptomatically.

# Update_Date:
2013-02-08 16:20:18 -0700

# Wikipedia_Link:
http://en.wikipedia.org/wiki/Ursodiol

# pKa_Isoelectric_Point:
Not Available

# Phase_1_Metabolizing_Enzyme_1_Gene_Name:
CYP2E1

# Phase_1_Metabolizing_Enzyme_1_ID:
6013

# Phase_1_Metabolizing_Enzyme_1_Name:
Cytochrome P450 2E1

# Phase_1_Metabolizing_Enzyme_1_Protein_Sequence:
>Cytochrome P450 2E1
MSALGVTVALLVWAAFLLLVSMWRQVHSSWNLPPGPFPLPIIGNLFQLELKNIPKSFTRL
AQRFGPVFTLYVGSQRMVVMHGYKAVKEALLDYKDEFSGRGDLPAFHAHRDRGIIFNNGP
TWKDIRRFSLTTLRNYGMGKQGNESRIQREAHFLLEALRKTQGQPFDPTFLIGCAPCNVI
ADILFRKHFDYNDEKFLRLMYLFNENFHLLSTPWLQLYNNFPSFLHYLPGSHRKVIKNVA
EVKEYVSERVKEHHQSLDPNCPRDLTDCLLVEMEKEKHSAERLYTMDGITVTVADLFFAG
TETTSTTLRYGLLILMKYPEIEEKLHEEIDRVIGPSRIPAIKDRQEMPYMDAVVHEIQRF
ITLVPSNLPHEATRDTIFRGYLIPKGTVVVPTLDSVLYDNQEFPDPEKFKPEHFLNENGK
FKYSDYFKPFSTGKRVCAGEGLARMELFLLLCAILQHFNLKPLVDPKDIDLSPIHIGFGC
IPPRYKLCVIPRS

# Phase_1_Metabolizing_Enzyme_1_SwissProt_ID:
P05181

# Drug_Target_1_Cellular_Location:
Cytoplasm (Potential)

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
19747134	Amaral JD, Sola S, Steer CJ, Rodrigues CM: Role of nuclear steroid receptors in apoptosis. Curr Med Chem. 2009;16(29):3886-902.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
AKR1C2

# Drug_Target_1_GenBank_ID_Gene:
U05598

# Drug_Target_1_GenBank_ID_Protein:
531160

# Drug_Target_1_GeneCard_ID:
AKR1C2

# Drug_Target_1_Gene_Name:
AKR1C2

# Drug_Target_1_Gene_Sequence:
>972 bp
ATGGATTCGAAATACCAGTGTGTGAAGCTGAATGATGGTCACTTCATGCCTGTCCTGGGA
TTTGGCACCTATGCGCCTGCAGAGGTTCCTAAAAGTAAAGCTCTAGAGGCCGTCAAATTG
GCAATAGAAGCCGGGTTCCACCATATTGATTCTGCACATGTTTACAATAATGAGGAGCAG
GTTGGACTGGCCATCCGAAGCAAGATTGCAGATGGCAGTGTGAAGAGAGAAGACATATTC
TACACTTCAAAGCTTTGGAGCAATTCCCATCGACCAGAGTTGGTCCGACCAGCCTTGGAA
AGGTCACTGAAAAATCTTCAATTGGACTATGTTGACCTCTATCTTATTCATTTTCCAGTG
TCTGTAAAGCCAGGTGAGGAAGTGATCCCAAAAGATGAAAATGGAAAAATACTATTTGAC
ACAGTGGATCTCTGTGCCACGTGGGAGGCCATGGAGAAGTGTAAAGATGCAGGATTGGCC
AAGTCCATCGGGGTGTCCAACTTCAACCACAGGCTGCTGGAGATGATCCTCAACAAGCCA
GGGCTCAAGTACAAGCCTGTCTGCAACCAGGTGGAATGTCATCCTTACTTCAACCAGAGA
AAACTGCTGGATTTCTGCAAGTCAAAAGACATTGTTCTGGTTGCCTATAGTGCTCTGGGA
TCCCATCGAGAAGAACCATGGGTGGACCCGAACTCCCCGGTGCTCTTGGAGGACCCAGTC
CTTTGTGCCTTGGCAAAAAAGCACAAGCGAACCCCAGCCCTGATTGCCCTGCGCTACCAG
CTGCAGCGTGGGGTTGTGGTCCTGGCCAAGAGCTACAATGAGCAGCGCATCAGACAGAAC
GTGCAGGTGTTTGAATTCCAGTTGACTTCAGAGGAGATGAAAGCCATAGATGGCCTAAAC
AGAAATGTGCGATATTTGACCCTTGATATTTTTGCTGGCCCCCCTAATTATCCATTTTCT
GATGAATATTAA

# Drug_Target_1_General_Function:
Involved in oxidoreductase activity

# Drug_Target_1_General_References:
10672042	Nishizawa M, Nakajima T, Yasuda K, Kanzaki H, Sasaguri Y, Watanabe K, Ito S: Close kinship of human 20alpha-hydroxysteroid dehydrogenase gene with three aldo-keto reductase genes. Genes Cells. 2000 Feb;5(2):111-25.
7959017	Qin KN, Khanna M, Cheng KC: Structure of a gene coding for human dihydrodiol dehydrogenase/bile acid-binding protein. Gene. 1994 Nov 18;149(2):357-61.
8011662	Ciaccio PJ, Tew KD: cDNA and deduced amino acid sequences of a human colon dihydrodiol dehydrogenase. Biochim Biophys Acta. 1994 Jun 28;1186(1-2):129-32.
8274401	Qin KN, New MI, Cheng KC: Molecular cloning of multiple cDNAs encoding human enzymes structurally related to 3 alpha-hydroxysteroid dehydrogenase. J Steroid Biochem Mol Biol. 1993 Dec;46(6):673-9.
9716498	Shiraishi H, Ishikura S, Matsuura K, Deyashiki Y, Ninomiya M, Sakai S, Hara A: Sequence of the cDNA of a human dihydrodiol dehydrogenase isoform (AKR1C2) and tissue distribution of its mRNA. Biochem J. 1998 Sep 1;334 ( Pt 2):399-405.

# Drug_Target_1_HGNC_ID:
HGNC:385

# Drug_Target_1_HPRD_ID:
11857

# Drug_Target_1_ID:
686

# Drug_Target_1_Locus:
10p15-p14

# Drug_Target_1_Molecular_Weight:
36736

# Drug_Target_1_Name:
Aldo-keto reductase family 1 member C2

# Drug_Target_1_Number_of_Residues:
323

# Drug_Target_1_PDB_ID:
1IHI

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF00248	Aldo_ket_red

# Drug_Target_1_Protein_Sequence:
>Aldo-keto reductase family 1 member C2
MDSKYQCVKLNDGHFMPVLGFGTYAPAEVPKSKALEAVKLAIEAGFHHIDSAHVYNNEEQ
VGLAIRSKIADGSVKREDIFYTSKLWSNSHRPELVRPALERSLKNLQLDYVDLYLIHFPV
SVKPGEEVIPKDENGKILFDTVDLCATWEAMEKCKDAGLAKSIGVSNFNHRLLEMILNKP
GLKYKPVCNQVECHPYFNQRKLLDFCKSKDIVLVAYSALGSHREEPWVDPNSPVLLEDPV
LCALAKKHKRTPALIALRYQLQRGVVVLAKSYNEQRIRQNVQVFEFQLTSEEMKAIDGLN
RNVRYLTLDIFAGPPNYPFSDEY

# Drug_Target_1_Reaction:
androsterone + NAD(P)+ = 5alpha-androstane-3,17-dione + NAD(P)H + H+

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
Works in concert with the 5alpha/5beta-steroid reductases to convert steroid hormones into the 3alpha/5alpha and 3alpha/5beta-tetrahydrosteroids. Catalyzes the inactivation of the most potent androgen 5-alpha-dihydrotestosterone (5alpha-DHT) to 5-alpha-androstane-3alpha,17beta-diol (3-alpha-diol)

# Drug_Target_1_SwissProt_ID:
P52895

# Drug_Target_1_SwissProt_Name:
AK1C2_HUMAN

# Drug_Target_1_Synonyms:
3-alpha-HSD3
Chlordecone reductase homolog HAKRD
DD/BABP
DD2
Dihydrodiol dehydrogenase 2
Dihydrodiol dehydrogenase/bile acid-binding protein
EC 1.-.-.-
EC 1.1.1.213
EC 1.3.1.20
Trans-1,2- dihydrobenzene-1,2-diol dehydrogenase
Type III 3- alpha-hydroxysteroid dehydrogenase

# Drug_Target_1_Theoretical_pI:
7.55

# Drug_Target_1_Transmembrane_Regions:
None

#END_DRUGCARD DB01586
